1/8
Looks like no tags are added yet.
Pharmacokinetic parameters for Drug Y are shown below. Which of the following statements best describes the PK changes that could be expected in advanced liver failure?
Eh = 0.95, Protein binding = 30%, Vd = 25L
A. Reductions in liver blood flow will reduce metabolism and significantly increase drug exposure
B. Reductions in protein binding will significantly increase drug exposure
C. Reductions in intrinsic clearance will significantly increase drug exposure
D. Volume overload caused by ascites will significantly increase drug exposure
A
Based on the Eh and extent of protein binding, Drug Y is a flow limited drug. Such drugs are affected by changes in liver blood flow.
Which of the following is most likely to be associated with structural changes in the liver resulting in pharmacokinetic alterations?
A. A history of alcoholic cirrhosis
B. Elevated AST/ALT resulting from shock liver
C. Drug-induced hepatotoxicity
D. Viral hepatitis A
A
Which of the following metabolic pathway is most likely to be impaired in severe liver disease?
A. CYP 3A4
B. Glucuronidation
A
Which of the following does NOT describe a pharmacokinetic or pharmacodynamic change and the corresponding effect one could expect in severe liver failure?
A. Hepatorenal syndrome decreases clearance of renally eliminated medications
B. Ascites decreases volume of distribution for hydrophilic medications
C. Increased blood brain barrier permeability leads to greater effects from drugs that work in the central nervous system
D. Decreased albumin concentrations result in a greater fraction unbound for highly albumin bound drugs
B
Pharmacokinetic parameters for Drug Y are shown below. Which of the following statements best describes the PK changes that could be expected in advanced liver failure?
Eh = 0.45, Protein binding = 90%, Vd = 50L
A. Reductions in liver blood flow will reduce metabolism and significantly increase drug exposure
B. Reductions in protein binding will significantly increase drug exposure
C. Reductions in intrinsic clearance will significantly increase drug exposure
D. Volume overload caused by ascites will significantly increase drug exposure
B
Based on the Eh and extent of protein binding, Drug Y is a flow limited drug. Such drugs are affected by changes in liver blood flow.
Which of the following statements is true about changes that occur in liver failure and their effect on pharmacokinetics and pharmacodynamics of some drugs?
A. Shunting of blood resulting from cirrhosis may result in increased drug metabolism
B. Ascities may cause increased volume of distribution for some drugs
C. Liver function assessment by MELD score is a reliable way of adjusting doses of most hepatically cleared drugs
D. Development of hepatorenal syndrome may lead to lower plasma concentrations of
drugs that are excreted unchanged in the urine
B
Which of the following is true regarding liver failure?
A. Metabolism by cytochrome pathways is more likely to be reduced than metabolism by glucuronidation in liver failure
B. If a patient taking a highly albumin bound drug becomes hypoalbuminemic but has preserved hepatic capacity, clearance will be slower than normal
C. Acute viral hepatitis commonly leads to significant changes in drug metabolism
D. When dosing hepatically cleared medications for patients with significant liver disease, one should start at the usual dose and titrate down the dose until the desired
response is achieved
A
Pharmacokinetic parameters for Drug X are shown below. Which of the following statements best describes the PK changes that could be expected in advanced liver failure?
Eh=0.95 Protein binding: 65% Vd = 2L
A. Reductions in liver blood flow will significantly increase drug exposure
B. Reductions in protein binding will significantly increase drug exposure
C. Reductions in intrinsic clearance will significantly increase drug exposure
D. Volume overload caused by ascites will significantly increase drug exposure
A
Pharmacokinetic parameters for Drug X are shown below. Which of the following statements best describes the PK changes that could be expected in advanced liver failure?
Eh= 0.5 Protein binding: 35% Vd = 200L
Excreted in the urine as 95% inactive metabolites
A. Reductions in liver blood flow will reduce metabolism and significantly increase drug exposure
B. Reductions in protein binding will significantly increase drug exposure
C. Reductions in intrinsic clearance will significantly increase drug exposure
D. Hepato-renal syndrome will significantly increase drug exposure
C